BNTC Benitec Biopharma Inc.
USHealthcareAs of 2026-10-08
Why BNTC matters now
Benitec Biopharma Inc. (BNTC) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.75 with -2.67% on the session and $300.6M in market capitalization; recent performance reads 1-month +13.34% and YTD -9.80%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-11.9M, and EPS of $-0.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.5%.
The latest indexable market news headline is "Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $25.00; recent insider activity includes Friedman David Matthew filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.27
P/S
0.00
EV/EBITDA
-2.53
DCF Value
$2.67
FCF Yield
-6.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-34.8%
ROA
-26.1%
ROIC
-29.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-11.9M | $-0.24 |
| Q2 2026 | $0.00 | $-11.8M | $-0.26 |
| Q1 2026 | $0.00 | $-9.0M | $-0.22 |
| Q4 2025 | $0.00 | $-16.1M | $-0.39 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$25.00
Target (Median)
$25.00
Target Range
$25.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.28
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.